CTs of the drug nadofaragene firadenovec (Adstiladrin®, Ferring Pharmaceuticals, Kastrup, Denmark), created based on an adenoviral vector with the IFNα2b gene (rAd-IFNa2b), demonstrated high efficacy in the treatment of bladder cancer—according to phase III CT results, 53% of patients achieved complete remission at 3 months, with 24% maintaining a response to therapy for 12 months [177,180]. The gene discussed is IFNA2; the disease is urinary bladder cancer.